Cyclophosphamide

證據等級: L5

預測適應症: 5 個

Cyclophosphamide: Preliminary Assessment — TxGNN Predictions Pending

One-Sentence Summary

Cyclophosphamide is a classical alkylating antineoplastic agent with established use across oncology and immunology. The current Evidence Pack does not contain TxGNN model predictions for new indications, and key data fields — including mechanism of action, safety warnings, and regulatory authorizations — remain to be populated. This report represents a preliminary structural assessment only; a full repurposing evaluation cannot proceed until the data pipeline is completed.

Quick Overview

Item	Content
Original Indication	Not retrieved in current data pipeline run
Predicted New Indication	No TxGNN predictions available
TxGNN Prediction Score	Not available
Evidence Level	Not assessable
New Zealand Market Status	Not marketed (0 authorizations found)
Number of Authorizations	0
Recommended Decision	Hold — critical data missing

Why is This Prediction Reasonable?

Mechanism of action data was not retrieved in the current Evidence Pack. Based on established pharmacological knowledge, Cyclophosphamide is a nitrogen mustard alkylating agent that covalently crosslinks DNA strands, thereby inhibiting replication and inducing apoptosis in rapidly dividing cells. It is also a prodrug requiring hepatic activation (primarily via CYP2B6 and CYP3A4) to its active metabolite 4-hydroxycyclophosphamide. This dual oncologic and immunosuppressive profile underlies its broad application across haematological malignancies, solid tumours, and autoimmune conditions.

Because the predicted_indications array is empty in this Evidence Pack, no TxGNN-driven repurposing candidate can be evaluated at this time. The TxGNN prediction step must be completed before a mechanistic linkage between Cyclophosphamide's known biology and any new candidate indication can be articulated.

Cytotoxicity

Cyclophosphamide meets all criteria for antineoplastic classification: it belongs to the alkylating agent / nitrogen mustard class and has established use in cancer treatment.

Item	Content
Cytotoxicity Classification	Conventional cytotoxic — Alkylating agent (nitrogen mustard class)
Myelosuppression Risk	High — bone marrow suppression is a primary dose-limiting toxicity; neutropenia nadir typically occurs 10–14 days post-administration, with thrombocytopenia and anaemia also common
Emetogenicity Classification	Moderate to High — dose-dependent; high-dose regimens (≥1,500 mg/m²) carry high emetogenic risk requiring prophylactic antiemetics
Monitoring Items	CBC with differential (weekly during active therapy), urinalysis and urine microscopy (hemorrhagic cystitis surveillance), serum creatinine and BUN, liver function tests (ALT, AST, bilirubin), electrolytes (especially sodium — SIADH risk at high doses)
Handling Protection	Must follow cytotoxic drug handling regulations; closed-system drug transfer devices (CSTD) required for preparation and administration

Safety Considerations

Please refer to the package insert for safety information.

Note: Safety warnings and contraindications were listed as data gaps in this Evidence Pack (DG001). The TFDA package insert query returned a success status (Query ID 4), but parsed content was not included in the output. Retrieval and structured parsing of the package insert is required before a formal safety assessment can be completed.

Conclusion and Next Steps

Decision: Hold

Rationale: The Evidence Pack is structurally incomplete — the TxGNN prediction step has not produced candidate indications, and two blocking or high-severity data gaps (DG001: TFDA safety warnings; DG002: mechanism of action) remain unresolved. No repurposing evaluation can be conducted without at least one ranked candidate indication to anchor the analysis.

To proceed, the following is needed:

Run TxGNN predictions for Cyclophosphamide (DB00531) to generate ranked candidate indications with scores
Retrieve MOA from DrugBank (DG002 — listed as High severity): query DrugBank API for DB00531 pharmacodynamics and mechanism fields
Parse TFDA package insert (DG001 — listed as Blocking): the insert was successfully retrieved (Query ID 4) but content was not structured; extract warnings, contraindications, and special population guidance
Investigate zero-authorization result: Cyclophosphamide has wide global availability; 0 TFDA licenses may reflect a search term mismatch (brand name vs. INN) rather than true non-registration — verify using brand names (e.g., Endoxan, Cytoxan)
Re-run evidence collection (clinical trials via ClinicalTrials.gov, literature via PubMed) for the top 3–5 TxGNN-predicted indications once predictions are available
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.